Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.

BMC pulmonary medicine - 13 Dec 2022

Podolanczuk Anna J, Kim John S, Cooper Christopher B, Lasky Joseph A, Murray Susan, Oldham Justin M, Raghu Ganesh, Flaherty Kevin R, Spino Cathie, Noth Imre, Martinez Fernando J

Abstract excerpt

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with few treatment options. N-acetylcysteine (NAC) is a well-tolerated, inexpensive treatment with antioxidant and anti-fibrotic properties. The National Heart, Lung, and Blood Institute (NHLBI)-sponsored PANTHER (Prednisone Azathioprine and NAC therapy in IPF) trial confirmed the harmful effects of immunosuppression in IPF, and did not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylcysteine
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Idiopathic Pulmonary Fibrosis

Share to Multicenter Studies as Topic

Share to Randomized Controlled Trials as Topic

Share to Treatment Outcome

Share to Vital Capacity

Source

Open in PubMed Open full text

Identifiers

PMID: 36514019
DOI: 10.1186/s12890-022-02281-8
PMCID: PMC9746571

Genes

TOLLIP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.PMID 36514019Read ↗

TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.Semantic proximity Read ↗

Pharmacogenetics and interstitial lung disease.Semantic proximity Read ↗

Risk of lung disease in the PI*SS genotype of alpha-1 antitrypsin: an EARCO research project.Semantic proximity Read ↗

Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPFSemantic proximity Read ↗

Single Nucleotide Polymorphisms (SNP) and SNP-SNP Interactions of the Surfactant Protein Genes Are Associated With Idiopathic Pulmonary Fibrosis in a Mexican Study Group; Comparison With Hypersensitivity Pneumonitis.Semantic proximity Read ↗

MICA-129Met/Val as a therapeutic compass in idiopathic pulmonary fibrosis: prognosis and antifibrotic benefit.Semantic proximity Read ↗

Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF.Semantic proximity Read ↗

Toll interacting protein gene polymorphisms in patients with systemic sclerosis: association with interstitial lung disease, outcome, and survivalSemantic proximity Read ↗

Association of rs3750920 polymorphism in TOLLIP with clinical characteristics of fibrosing interstitial lung diseases in JapaneseSemantic proximity Read ↗

Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study.Semantic proximity Read ↗

Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.Semantic proximity Read ↗

Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.